Publication: EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
Loading...
Date
2023-07-04
Authors
Hidalgo-Tenorio, Carmen ; Sadyrbaeva-Dolgova, Svetlana ; Enríquez-Gómez, Andrés ; Muñoz, Patricia ; Plata-Ciezar, Antonio ; Miró, Jose Maria ; Alarcón, Arístides de ; Martínez-Marcos, Francisco Javier ; Loeches, Belén ; Eschiruela- Vidal, Francesc ; Vinuesa, David ; Herrero, Carmen ; Badia-Martí, Cristina ; Arenas, María del Mar ; García-Vázquez, Elisa ; Arnaiz de las Revillas, Francisco ; Pasquau, J. ; EN-DALBACEN study group
item.page.secondaryauthor
item.page.director
Publisher
Elsevier
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1016/j.ijantimicag.2023.106918
item.page.type
info:eu-repo/semantics/article
Description
© 2023 The Author(s). Published by Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. This document is the accepted, version of a Published Work that appeared in final form in International Journal of Antimicrobial Agents . To access the final edited and published work see https://doi.org/10.1016/j.ijantimicag.2023.106918
Abstract
Infective endocarditis (IE) has high mortality and morbidity and requires long hospital stays to deliver the antibiotic treatment recommended in clinical practice guidelines. The objectives were to analyze the health outcomes of the use of dalbavancin (DBV) in the consolidation treatment of IEs caused by Gram-positive cocci (GPC) and to perform a pharmacoeconomic study. Material and methods:
This observational, retrospective, Spanish multicenter study in patients with IE who received DBV as part of antibiotic treatment in consolidation phase and were followed for at least 12 months. The study was approved by the Provincial Committee of the coordinating center. Results:
The study included 124 subjects, 70.2% male, with a mean age of 67.4 years and median Charlson index of 4 (IQR:2.5-6). Criteria for definite IE were met by 91.1%. Coagulase-negative staphylococci (38.8%), Staphylococcus aureus (22.6%), Enterococcus faecalis (19.4%), Streptococcus spp. (9.7%) were isolated more frequently, all susceptible to vancomycin. Before DVB administration, 91.2% had undergone surgery, 60.5% had received a second regimen for 24.5 days (16.6-56), and 20.2% a third regimen for 14.5 days (12-19.5). DBV was administered to facilitate discharge in 95.2% of cases. At 12 months, the effectiveness
was of 95.9%, there was 0.8% loss to follow-up, 0.8% IE-related death and 3.2% relapse. Adverse events were recorded in 3.2%. The hospital stay was reduced by 14 days and there was a mean saving of 5,548.57€/patient versus conventional treatments. Conclusion:
DBV is highly effective, safe, and cost-effective as consolidation therapy in patients with IE by GPC, with few adverse events.
publication.page.subject
Citation
International Journal of Antimicrobial Agents. 2023, 62(3):106918
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/